Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bio-Works Technologies AB's annualizedNet Income for the quarter that ended in Mar. 2026 was €1.74 Mil.
Bio-Works Technologies AB's average Total Assets over the quarter that ended in Mar. 2026 was €6.53 Mil. Therefore, Bio-Works Technologies AB's annualized ROA % for the quarter that ended in Mar. 2026 was 26.60%.
The historical rank and industry rank for Bio-Works Technologies AB's ROA % or its related term are showing as below:
FRA:1BD'
s ROA % Range Over the Past 10 Years
Min: -73.91 Med: -49.07 Max: -4.32
Current: -4.32
During the past 11 years, Bio-Works Technologies AB's highest ROA % was -4.32%. The lowest was -73.91%. And the median was -49.07%.
FRA:1BD's ROA % is ranked worse than 60.14% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.73
vs FRA:1BD: -4.32
Bio-Works Technologies AB (FRA:1BD) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bio-Works Technologies AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Works Technologies AB ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Works Technologies AB's ROA % distribution charts can be found below:
* The bar in red indicates where Bio-Works Technologies AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Bio-Works Technologies AB (FRA:1BD) has a ROA % of 26.60% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bio-Works Technologies AB and its competitors. According to the industry distribution chart, Bio-Works Technologies AB ranks #513 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 60.1%.
Is Bio-Works Technologies AB's ROA % too high?
Bio-Works Technologies AB's current ROA % is 26.60%. The Medical Devices & Instruments industry median ROA % is 0.73. Bio-Works Technologies AB's value of 26.60% is 3543.8% above this industry median. Based on the distribution chart, Bio-Works Technologies AB ranks #513 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio-Works Technologies AB has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Works Technologies AB's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio-Works Technologies AB ranks #513 out of 853 companies for ROA %. This places Bio-Works Technologies AB in the lower half of its industry. The industry median ROA % is 0.73. Bio-Works Technologies AB's value of 26.60% is 3543.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.73, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Works Technologies AB's current ROA % of 26.60% is 3543.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bio-Works Technologies AB and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Works Technologies AB's current ROA % is 26.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Works Technologies AB stock overvalued right now?
Based on GuruFocus' analysis, Bio-Works Technologies AB (FRA:1BD) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.32, compared to a current price of €0.29 — trading 10.6% below its estimated fair value. The current ROA % is 26.60% and 3543.8% above the Medical Devices & Instruments industry median of 0.73. Bio-Works Technologies AB's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Bio-Works Technologies AB (FRA:1BD), the current ROA % is 26.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Works Technologies AB (FRA:1BD) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Works Technologies AB stock appears to be undervalued.
The current stock price of €0.29 is trading 10.6% below its estimated GF Value™ of €0.32.
GuruFocus considers Bio-Works Technologies AB to be Modestly Undervalued.
Key valuation signals for FRA:1BD:
ROA %: 26.60%
GF Value™: €0.32 vs. price of €0.29 (10.6% below fair value)
Industry Position: 3543.8% above the Medical Devices & Instruments median (#513 of 853)
No single metric tells the full story. See the FRA:1BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.
49GF Score
Get the complete analysis for FRA:1BD
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1BD has been successfully added to your 
